Private companies, of course, often have fiduciary responsibilities to shareholders and have a very different role than public sector institutions or charities. But we must find creative solutions, looking to public-private partnerships and other tools. We must find programs that improve the lives of the poor, promote long-term acceptance of this technology and help advance the goals of all concerned. A second issue is the need for adequate regulatory structures. Like any new technology, modern biotechnology presents risks that must be managed.
Environmental testing is important, for example, to ensure gene transfer issues are addressed.
Issues related to pest resistance may be important. This Administration is deeply committed to helping developing countries build adequate regulatory systems to manage and address biotechnology. We look forward to discussions among staff to resolve technical issues and to working together to secure passage of this legislation. The programs described in S. 2106 can help developing countries establish regulatory systems to assess the opportunities and potential risks associated with modern biotechnology. A final barrier is lack of knowledge and fear.